Strontium-89 for bone metastases from prostate cancer:An update
ZHAO Wei-wei
XIE Peng
DENG Hou-fu
Abstract：Strontium-89 (Sr-89 ) is a pure emitter with maximum beta energy of 1.46 MeV,average beta energy of 0.58 MeV,and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is > 50 days at the metastatic sites,but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 ± 4 to 231 ± 56 cGy/MBq,2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer,with analgesic effectiveness in 80%.
Keywords：strontium-89radiotherapyprostate carcinomabone metastasisbone pain palliation
Publication Date：2010-03-02
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 269-272 )